Articles related to SMALL CELL LUNG CANCER (SCLC)

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

Adjuvant durvalumab therapy led to a median overall survival of 55.9 months compared to 33.4 months with placebo in patients with limited-stage small-cell lung cancer who did not progress after chemoradiotherapy.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.

The phase 3 EXTENTORCH trial has demonstrated the potential of toripalimab plus chemotherapy as a new standard first-line therapy for ES-SCLC, with a median progression-free survival of 5.8 months.

This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.

Explore how high-dose hyperfractionated thoracic radiotherapy is setting new standards in LS-SCLC treatment.